TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation
Open Access
- 16 December 2024
- journal article
- research article
- Published by Springer Nature in Nature Cancer
- Vol. 5 (12) , 1834-1851
Abstract
Blockade of immune checkpoints PD-1 and TIGIT has demonstrated activity in mouse tumor models and human patients with cancer. Although these coinhibitory receptors can restrict signaling in CD8+ T cells by regulating their associated co-stimulatory receptors CD28 and CD226, the functional consequences of combining PD-1 and TIGIT blockade remain poorly characterized. In mouse tumor models, we show that combination blockade elicited CD226-driven clonal expansion of tumor antigen-specific CD8+ T cells. The expanded clones emerged from a population of stem-like cells in draining lymph nodes, entering the blood as a previously unidentified single-phenotype, multiclonal population. Upon reaching the tumor, these transiting cells expanded further and differentiated into effector or exhausted T cells, with combination blockade restricting entry into the exhaustion pathway by favoring co-stimulation. Thus, PD-1 and TIGIT inhibition helps shape the repertoire of tumor-reactive CD8+ T cells in draining lymph nodes and determines their immunological fate in the tumor to enhance therapeutic benefit. Analysis of clinical trial samples suggests a similar mechanism may also occur in patients with cancer.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid TumorsJAMA Oncology, 2023
- The cancer-immunity cycle: Indication, genotype, and immunotypeImmunity, 2023
- CD8+ T cells in the cancer-immunity cycleImmunity, 2023
- Dendritic cells as shepherds of T cell immunity in cancerImmunity, 2023
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responsesImmunity, 2022
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T CellsImmunity, 2019
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector FunctionCancer Cell, 2014